Navigation Links
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Date:10/29/2009

aggressive chemotherapy and radiotherapy by Wolff et al (J Neuro Oncology Vol. 79. #3, September 2006).

The multi-centre, open-label, single-arm study was completed in 2007 and designed to evaluate the effectiveness of nimotuzumab combined with radiation in children with newly diagnosed DIPG, an inoperable form of brain cancer for which treatment options are severely limited. The study enrolled 42 patients aged 3 to 16 years (median 7 years) between April 2006 and August 2007, with 41 patients evaluable for response. The primary endpoint is reported to be "probability of a patient surviving progression-free six months post-diagnosis or median PFS over six months" and secondary endpoints included overall survival, response rate, toxicity and quality of life. The principal investigator is Professor Udo Bode at the University of Bonn, Germany.

"Nimotuzumab continues to demonstrate efficacy in trials throughout the world while avoiding the severe toxicities of the currently available EGFR-targeting drugs," said David Allan, Chairman and CEO of YM BioSciences. "These results underscore the value of a drug that can deliver benefit while maintaining quality of life. Adding to the body of safety and efficacy data for nimotuzumab, 48-month survival data from the randomized 4-arm "BEST" trial will be presented at ASTRO 2009 which will permit reviewers to observe the activity and efficacy of nimotuzumab in the absence of the severe toxicities of the class."

YM is currently conducting a Phase II study in children suffering from recurrent DIPG at ten of the principal oncology hospitals in the US as well as sites in Canada and Israel, with data expected in 2010. The drug is available on a compassionate use basis in the US for children with pediatric glioma and is designated an Orphan Drug for adult and pediatric glioma by the FDA as well as the EMEA for Europe.

ASTRO Presentation

An oral presentation will be delivered at th
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 29, 2014  Ten of the most highly-respected ... repair, regeneration, allograft reconstruction and research and development, ... gathered to discuss the future of cartilage regeneration ... Medicine symposium, Cartilage Regeneration: State of the ... Biosurgery, Minced Juvenile Allograft, and State of the ...
(Date:9/29/2014)... security, emerging diseases and biodiversity loss requires evolutionary ... Science Express that was co-authored by ... of Agriculture and Life Sciences. , For the ... has reviewed progress in addressing a broad set ... using approaches that consider evolutionary histories and the ...
(Date:9/29/2014)... According to the ... (Modifying Enzymes, DNA Polymerase, Acetylase, Methyltransferase, Instruments ... by Research Area (Developmental Biology, Oncology), by ... published by MarketsandMarkets, provides a detailed overview ... market trends, and strategies impacting the global ...
(Date:9/29/2014)... Sept. 29, 2014  Atlas Venture, an early stage ... technology innovation, today announced that Jason Rhodes , ... EPZM ), is joining the firm,s life sciences ... At Atlas, Rhodes will work closely with ... brings an accomplished record in company creation, deal making ...
Breaking Biology Technology:World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2
(Date:9/30/2014)... KONG , Sept. 30, 2014 Winners of ... Economist Events, Innovation Summit scheduled to take place at the JW ... the summit, the award winners will share their experiences and the ... who have made a proven innovation over the past decade, will ... the night before the summit. It will be the first ...
(Date:9/29/2014)... Washington, DC Monday, September 29: Between 1970 ... and fish around the globe dropped 52 percent, ... by World Wildlife Fund (WWF). This biodiversity loss ... increasing resource use of high-income countries. , In ... the report,s data point to other warning signs ...
(Date:9/29/2014)... of Texas at Arlington research team says recently identified ... their lab could open doors for homeland security and ... in the Oct. 1 issue of Optics Letters ... co-authors describe a new method to fabricate transparent nanoscintillators ... until a transparent ceramic is formed. A scintillator ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Half of global wildlife lost, says new WWF report 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... scientists have begun to harness DNA,s powerful molecular machinery ... natural ability of pairs of DNA molecules to assemble ... the California Institute of Technology,* could provide a means ... and drug delivery systems, from the bottom up. ...
... . Sperm have only one aim: to find ... emitting attractants. Calcium ions determine the beating pattern of the sperm ... the Max Planck Institute for the Physics of Complex Systems in ... centre in Bonn, an institute of the Max Planck Society, have ...
... British Columbia is arguably the most important fossil deposit ... Cambrian "Explosion," the rapid flowering of complex life from ... comprised of shells, teeth and bones, the Burgess Shale ... delicate structuresof animals belonging to Earth,s earliest complex ecosystems ...
Cached Biology News:The shape of things to come: NIST probes the promise of nanomanufacturing using DNA origami 2Sperm can count 2Mechanism for Burgess Shale-type preservation 2
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
... system is designed for multiple user laboratories ... for TLC applications. The MultiDoc-It is available ... enclosure provides a darkroom environment and protects ... Use image capture and enhancement , ...
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Request Info...
Biology Products: